Company

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia
Lepu Medical TechnologySHE: 300003

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Lepu Medical Technology (Beijing) Co., Ltd. (SHE: 300003) announced that MWX205 Injection, a dual‑target small interfering RNA (siRNA) drug independently developed by its controlled subsidiary Shanghai Minwei Biotechnology Co., Ltd.…

IASO Bio's In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

IASO Bio’s In Vivo CAR‑T IASO208 Clears NMPA IND – CD20‑Targeting Therapy Heads to Phase Ib in the US for R/R B‑NHL

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

AstraZeneca Acquires Omniose – Vaccine Bioconjugation Specialist Bolsters Bacterial Threat Defense Within Infectious Disease Unit

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Kelun-Biotech's Anti-HER2 ADC A166 Receives NMPA Review for Expanded Indication
ADC / XDCHER2

Kelun-Biotech’s Anti-HER2 ADC A166 Receives NMPA Review for Expanded Indication

PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration
AINYSE: PFE

PostEra Expands Partnership with Pfizer to Launch New ADC Collaboration

Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline
AIETR: MRK

Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline

Hansoh and GSK's HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma
ADC / XDCBreakthrough therapy

Hansoh and GSK’s HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma

Show More